Abstract 5917
Background
The increase in cancer survival and the development of new therapies has produced an increase in the hospital admissions through the Emergency Department (ED). To assess these patients and their outcome, we designed this study.
Methods
The records of patients admitted between July and November 2018 were studied. The following variables were registered: age, gender, comorbidities, type of cancer, stage, type and line of treatment, date of the last treatment, symptoms at admission, hospitalization length and outcome.
Results
170 patients (83 men and 87 women) entered the study. The mean age was 61.4 years. The most frequent diagnoses were: lung (20%), breast (17.1%), colo-rectal (14.7%) and pancreatic (12.4%) cancers. Stages: I – II (15.5%), III (10.6%) and IV (75.9%). Type of therapy: chemotherapy (74.1%), immunotherapy (9.4%), targeted therapy (16.5%) and homone therapy (2.4%). Line of therapy: neo- or adjuvant (18%), first (46.6%), second (18%), third (9.9%) and fourth or subsequent (7.5%). The most frequent symptoms at admission were: fever (31.4%), dyspnoea (14.8%) and pain 14.8%). Thirty seven point six percent of admissions were because of tumour related complications, 34.7% because of toxicity and 27.1% because of non-leukopenic infection. The mean hospitalization length were 10.3 days. From the 170 patients, 32 died in the hospital and 13 within the first month after discharge. Tumour progression was the cause of death in 75% of the cases and the complications of therapy was in 18.2%. Seventy five percent were receiving a third or subsequent line of therapy and 66.5% received chemotherapy in the last month of life.
Conclusions
Despite all patients were managed according the ESMO and NCCN guidelines, there is a necessity to improve the clinical decisions, in order to improve the patients’ quality of life and the uses of hospital resources. The establishment of Clinical Decision Units in the ED, could help to this goal. Or perhaps there is a “missing link” between guidelines and the real clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Manuel Morales González.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract